Table 3.

Lymphocyte proliferation after stimulation with virus strains in patients and healthy controls

Healthy controlsNontreated mRCC controlsSunitinib-treated patientsSorafenib-treated patients
n =11n = 7n = 16n = 6
Mean proliferative indexaRangeMean proliferative indexaRangeP versus HCMean proliferative indexaRangeP versus HCMean proliferative indexaRangeP versus HC
H3N2
Baseline5.073.40–6.045.524.63–7.030.3194.803.40–6.210.4164.092.40–6.260.091
Day 85.564.65–6.325.524.57–6.680.9085.283.99–7.060.3294.864.58–5.610.010
Day 8- baseline0.48−0.89–2.920.00−0.88–1.300.3010.48−0.42–3.480.9920.78−1.57–2.390.638
H1N1
Baseline5.073.47–6.495.534.57–7.170.3214.883.61–6.360.5814.072.48–6.030.087
Day 85.424.55–6.385.343.95–6.380.8315.463.91–7.980.8934.874.34–5.860.064
Day 8- baseline0.35−1.33–2.57−0.19−1.72–0.920.2950.58−0.66–3.760.6040.80−1.14–2.730.466
B
Baseline5.002.94–5.895.624.84–7.200.2014.803.18–6.000.5684.303.04–6.360.233
Day 85.484.67–5.915.394.33–6.620.7675.294.09–6.550.4674.764.36–5.420.007
Day 8- baseline0.48−1.04–2.80-0.23−1.36–0.750.1520.49−1.03–2.240.9830.47−1.08–2.380.978

Note: The mean logarithmic lymphocyte proliferation after stimulation with virus strain at base line and day 8 in the healthy controls and the patient groups (nontreated mRCC controls, sunitinib-treated patients, and sorafenib-treated patients). The difference between each of the patient groups and the healthy controls in mean proliferation from baseline to day 8 was tested with the t-test.

  • aThe mean proliferative index is calculated as proliferation of virus-stimulated PBMC cultures relative to proliferation in PBMC cultures with only medium.